TAXA DE ERRADICAÇÃO DO HELICOBACTER PYLORI E FATORES ASSOCIADOS EM INDIVÍDUOS DE UMA CLÍNICA DO MUNICÍPIO DE FLORIANÓPOLIS
DOI:
https://doi.org/10.63845/aqgrh714Palavras-chave:
Helicobacter pylori. Tratamento. Erradicação.Resumo
A infecção pelo Helicobacter pylori(H.pylori) está relacionada à patogênese de diversas doenças como gastrite crônica, adenocarcinoma gástrico, úlcera péptica. Tendo em vista a diminuição da erradicação do H.pylorinos últimos anos, objetivou-se avaliar a taxa da erradicação da infecção pelo H.pylorie fatores associados em indivíduos de uma clínica do município de Florianópolis. Foram coletados dados de prontuários de 79 pacientes de 17 a 80 anos, com diagnóstico da infecção a partir do teste rápido da urease e que realizaram o tratamento entre os meses de novembro de 2016a novembro de 2017. A erradicação foi determinada a partir do teste rápido da urease e teste histológico após, pelo menos, quatro semanas do término do tratamento. O estudo foi conduzido em uma clínica particular em Florianópolis, referência em Gastroenterologia. A taxa de erradicação geral do H.pylorifoi de 75,9%. Em indivíduos com idade inferior a 50 anos, observou-se erradicação em 84,4% (RP: 1,30; IC: 0,99-1,72; p<0,05), destes, a maioria realizou o tratamento de primeira linha. Em indivíduos que utilizaram a primeira linha de tratamento a erradicação foi de 83,6% (RP:1,60; IC:1,05-2,44; p=0,005). Com relação ao número de vezes em que foi realizado o tratamento, observou-se uma taxa de erradicação de 84% (RP:1,60; IC:1,05-2,45; p<0,05) em pacientes que nunca realizaram o tratamento. A taxa de erradicação foi significativamente maior em indivíduos com idade inferior a 50 anos, quando administrado o tratamento de primeira linha com claritromicina e amoxicilina por sete dias e que realizaram o tratamento pela primeira vez.
Referências
Joo YE, Park HK, Myung DS, et al. Prevalence and Risk Factors of Atrophic Gastritis and Intestinal Metaplasia: A Nationwide Multicenter Prospective Study in Korea. Gut Liver. 2013;7:303-10. DOI: https://doi.org/10.5009/gnl.2013.7.3.303
Basiri Z, Safaralizadeh R, Bonyadi MJ, et al. Helicobacter pylori vacA d1 genotype predicts risk of gastric adenocarcinoma and peptic ulcers in northwestern Iran. Asian Pac J Cancer Prev. 2014;15:1575-9. DOI: https://doi.org/10.7314/APJCP.2014.15.4.1575
Parsonnet JS, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994; 5:330:1267–71. DOI: https://doi.org/10.1056/NEJM199405053301803
Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan.Gut. 2012; 61:507-13. DOI: https://doi.org/10.1136/gutjnl-2011-300495
International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 1994; 61:1-241.
Porras C, Nodora J, Sexton R, et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control. 2013;24:209-15. DOI: https://doi.org/10.1007/s10552-012-0117-5
Calvet X, Ramirez Lazaro MJ, Lehours P, et al. Diagnosis and Epidemiology of Helicobacter pylori Infection. Helicobacter. 2013;18:5-11. DOI: https://doi.org/10.1111/hel.12071
Cave DR. Transmission and epidemiology of Helicobacter pylori. Am J Med 1996; 100: 12S-17S; discussion 17S-18S. DOI: https://doi.org/10.1016/S0002-9343(96)80224-5
Pan KF, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication.Gut. 2016; 65:9-18. DOI: https://doi.org/10.1136/gutjnl-2015-309197
Trindade LMDF, Menezes LBO, Neta AMS, et al. Prevalence of Helicobacter pylori Infection in Samples of Gastric Biopsies. Gastroenterol Res. 2017;10:33-41. DOI: https://doi.org/10.14740/gr785w
Reis Júnior JDD. Soroprevalência da infecção por Helicobacter pylori em uma amostra rural do Estado do Amazonas, Brasil. Rev Pan-Amaz Saude. 2012;3:33-6. DOI: https://doi.org/10.5123/S2176-62232012000100005
Zaterka S, Eisig JN, Chinzon D, et al. Factors Related to Helicobacter pylori Prevalence in an Adult Population in Brazil. Helicobacter. 2007;12:82–8. DOI: https://doi.org/10.1111/j.1523-5378.2007.00474.x
Genta RM, Turner KO, Sonnenberg A. Demographic and socioeconomic influences on Helicobacter pylori gastritis and its pre-neoplastic lesions amongst US residents. Aliment Pharmacol Ther. 2017;46:322-30. DOI: https://doi.org/10.1111/apt.14162
Xia Y, Meng G, Zhang Q, et al. Dietary Patterns are Associated with Helicobacter Pylori Infection in Chinese Adults: A Cross-Sectional Study. Sci. Rep. 2016;6:32334. DOI: https://doi.org/10.1038/srep32334
Zhou X, Zhang C, Wu J, et al. Association between Helicobacter pylori infection and diabetes mellitus: A meta-analysis of observacional studies. Diabetes Res Clin Pract. 2013; 99:200-8. DOI: https://doi.org/10.1016/j.diabres.2012.11.012
Kibru D, Gelaw B, Alemu A, et al. Helicobacter pylori infection and its association with anemia among adult dyspeptic patients attending Butajira Hospital, Ethiopia. BMC Infectious Diseases. 2014;14:656. DOI: https://doi.org/10.1186/s12879-014-0656-3
Coelho LGV, Marinho JR, Genta R, et al. IVth Brazilian Consensus Conference on Helicobacter pylori infection. Arq. Gastroenterol. 2018; pii: S0004-28032018005001101. doi: 10.1590/s0004-2803.201800000-20. DOI: https://doi.org/10.1590/s0004-2803.201800000-20
Kim SE, Park MI, Park SJ, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30:801-7. DOI: https://doi.org/10.3904/kjim.2015.30.6.801
Sasaki M, Ogasawara N, Utsumi K, et al. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr. 2010;47:53-8. DOI: https://doi.org/10.3164/jcbn.10-10
Felga G, Silva FM, Barbuti RC, et al. Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients. J Infect Dev Ctries. 2010;4:712–16. DOI: https://doi.org/10.3855/jidc.911
Coelho LG, Mattos AA, Francisconi CFM, et al. Efficacy of the dosing regimen of pantoprazole 40 mg, amoxicillin 1000 mg and clarithromycin 500 mg, twice daily for 7 days, in the eradication of Helicobacter pylori in patients with peptic ulcer. Arq Gastroenterol. 2004;41:71-6. DOI: https://doi.org/10.1590/S0004-28032004000100014
Bellelis P, Samano EST, Nunes RC, et al. Efficacy of a triple therapy for Helicobacter pylori eradication in a well-developed urban area in Brazil. Sao Paulo Med J. 2004;122:73-5. DOI: https://doi.org/10.1590/S1516-31802004000200009
Kim BJ, Kim HS, Song HJ, et al. Korean College of Helicobacter and Upper Gastrointestinal Research. Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis. J Korean Med Sci. 2016;31:1246-53. DOI: https://doi.org/10.3346/jkms.2016.31.8.1246
Queiroz DM, Dani R, Silva LD, et al. Factors Associated With Treatment Failure of Helicobacter pylori Infection in a developing country. J Clin Gastroenterol. 2002;35:315–20. DOI: https://doi.org/10.1097/00004836-200210000-00007
Abdullahi M, Annibale B, Capoccia D, et al. The eradication of Helicobacter pylori is affected by Body Mass Index (BMI). Obes Surg. 2008;18:1450-4. DOI: https://doi.org/10.1007/s11695-008-9477-z
Camargo MC, Piazuelo MB, Mera RM, et al. Effect of smoking on failure of H.pylori therapy and gastric histologic in a high gastric cancer risk area of Colombia. Acta Gastroenterol Latinoam. 2007;37:238-45.
Sapmaz F, Kalkan IH, Suslu I, et al. Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus. J Dig Dis. 2015;16:531-6. DOI: https://doi.org/10.1111/1751-2980.12272
Kotilea K, Mekhael J, Salame A, et al. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;00:12383. DOI: https://doi.org/10.1111/hel.12383
Lee JY, Kim N, Kim MS, et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci. 2014; 59:1235-43. DOI: https://doi.org/10.1007/s10620-014-3093-7
Seck A, Burucoa C, Dia D, et al. Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. Ann Clin Microbiol Antimicrob. 2013;12:1-5. DOI: https://doi.org/10.1186/1476-0711-12-3
Camargo MC, Garcia A, Riquelme A, et al. The Problem of Helicobacter pylori Resistance to Antibiotics: A Systematic Review in Latin America. Am J Gastroenterol. 2014;109:485–95. DOI: https://doi.org/10.1038/ajg.2014.24
Boyanova L, Gergova G, Markovska R, et al. Primary Helicobacter pylori resistance in elderly patients over 20 years: A Bulgarian study. Diagn Microbiol Infect Dis. 2017;88:264-7. DOI: https://doi.org/10.1016/j.diagmicrobio.2017.05.001
Macías-García F, Llovo-Taboada J, Díaz-López M, et al. High primary antibiotic resistance of Helicobacter pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. 2017;22:e12440. DOI: https://doi.org/10.1111/hel.12440
Coelho LG, Maguinilk I, Zaterka S, et al. 3rd Brazilian Consensus on Helicobacter pylori. Arq. Gastroenterol. 2013;50:81-96. DOI: https://doi.org/10.1590/S0004-28032013005000001
Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol. 2009;7:145-8. DOI: https://doi.org/10.1016/j.cgh.2008.10.024
Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017; 112:212-39. DOI: https://doi.org/10.1038/ajg.2016.563
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. DOI: https://doi.org/10.1136/gutjnl-2016-312288
Suzuki RB, Lopes RA, da Camara Lopes GA, et al. Low H. pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of Sao Paulo, Brazil. BMC Gastroenterol. 2013;13:164. DOI: https://doi.org/10.1186/1471-230X-13-164
Sanches BS, Martins GM, Lima K, et al. Detection of H. pylori resistance to clarithromycin and fluorquinolones in Brazil: A national survey. World J Gastroenterol. 2016;22:7587-94. DOI: https://doi.org/10.3748/wjg.v22.i33.7587
Martins GM, Sanches BSF, Moretzsohn LD, et al. Molecular detection of clarithromycin and fluoroquinolones resistance in H. pylori infection, directly applied to gastric biopsies, in an urban Brazilian population. Arq Gastroenterol. 2016;53:113-7. DOI: https://doi.org/10.1590/S0004-28032016000200012
Eisig JN, Silva FM, Barbuti RC, et al. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq. Gastroenterol. 2011;48:261-4. DOI: https://doi.org/10.1590/S0004-28032011000400008
Lins AK, Lima RA, Magalhaes M. Clarithromycin-resistant H. pylori in Recife, Brazil, directly identified from gastric biopsies by polymerase chain reaction. Arq Gastroenterol. 2010;47:379-82. DOI: https://doi.org/10.1590/S0004-28032010000400011
Picoli SU, Mazzoleni LE, Fernández H, et al. Resistance to amoxicillin, clarithromycin and ciprofloxacin of H. pylori isolated from Southern Brazil patients. Rev Inst Med Trop Sao Paulo. 2014;56:197-200. DOI: https://doi.org/10.1590/S0036-46652014000300003
Muñoz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, et al. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter. 2018;23:e12452. DOI: https://doi.org/10.1111/hel.12452
Silva FM, Queiroz EC, Navarro-Rodriguez T, et al. Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers. Clinics. 2015;70:318-21. DOI: https://doi.org/10.6061/clinics/2015(05)02
Wueppenhorst N, Stueger HP, Kist M, et al. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. J Antimicrob Chemother.2013;68:1562-6. DOI: https://doi.org/10.1093/jac/dkt061
Liou JM, Chang CY, Chen MJ, et al. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict 74. Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. PLoS ONE. 2015;10:e0124199. DOI: https://doi.org/10.1371/journal.pone.0124199
Yakoob J, Jafri W, Abbas Z, et al. Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area. Epidemiol Infect. 2011;139:581-90. DOI: https://doi.org/10.1017/S0950268810001226
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2019 Arquivos Catarinenses de Medicina
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
